Aldo-keto reductase family 1 B10 (AKR1B10) is a member of the NADPH-dependent aldo-keto reductase (AKR) superfamily, and has been considered to be a potential cancer therapeutic target. Total extract from the bark of Rhus verniciflua (Toxicodendron vernicifluum (Stokes)) showed AKR1B10 inhibitory activity. To identify the active compounds from R. verniciflua responsible for AKR1B10 inhibition, nine compounds were isolated via bioactivity-guided isolation and tested for their effects against recombinant human AKR1B10 (rhAKR1B10). Results showed that butein, isolated from the ethyl acetate fraction, was most able to inhibit rhAKR1B10. The inhibitory rate of butein against rhAKR1B10 was 42.86% at 1 μM with an IC50 value of 1.47 μM, and enzyme kinetic analysis revealed its inhibition mode to be uncompetitive. [BMB reports 2010; 43(4): 268-272]
INTRODUCTION
Aldo-keto reductase family 1 B10 (AKR1B10), also identified as aldose reductase-like or small intestine aldose reductase (ARL-1), is a recently identified member of the aldo-keto reductase (AKRs) superfamily (1). AKR1B10 is a NADPH-dependent oxidoreductase and reduces various aldehydes and ketones, including endogenous substrates such as retinals, farnesal and geranylgeranial (2, 3). AKR1B10 is, however, highly expressed in several types of cancers, including hepatocellular carcinoma (4), lung squamous cell carcinoma, lung adnocarcinoma in smokers (5) and cervical cancer (6). AKR1B10 is also known to be highly active in the reduction of all-trans-and 9-cis-retinaldehyde, with efficiency comparable to retinaldehyde reductase. Thus, an increase in AKR1B10 activity seriously inhibits retinoic acid synthesis, which can be associated with subsequent loss of cell differentiation and cancer development (7). Recent work showed that down-regulation of the AKR1B10 gene using siRNA promoted cell death in colorectal cancer cells through enhanced cytotoxicity of reactive carbonyls produced from lipid peroxidation (8). In other studies, inhibition of AKR1B10 resulted in disruption of lipid synthesis, mitochondrial function and oxidative status, all of which are involved in important cell survival mechanisms (9, 10). Therefore, AKR1B10 is a potential therapeutic target in certain types of cancer, but specific AKR1B10 inhibitors are not yet clinically available.
Another AKR protein, Aldo-keto reductase family 1 B1 (AKR1B1) has to date been the most studied member of the AKR superfamily because it is involved in important biological processes. Also called aldose reductase (ALR2), AKR1B1 is up-regulated in hyperglycemia and reduces glucose to sorbitol, a hyperosmotic compound, which results in cellular accumulation of sorbitol. This hyperglycemic injury triggers development of secondary diabetic complications, including cataract formation in the lens (11), neuropathy (12), nephropathy (13) and retinopathy (14). Thus, much effort has been focused on finding inhibitors of AKR1B1 (ARIs) for therapeutic purposes against diabetic complications. It requires, however, further mechanistic study because knowing the mechanism would allow the development of clinical drugs without unwanted side effects. Interestingly, AKR1B1 and AKR1B10 show about 71% homology in their amino acid sequences (15), and also show similar substrate specificity towards several endogenous substrates, such as retinals (2), phospholipid aldehydes (16), and acrolein (8). For this reason, selective ARIs might also be inhibitors for AKR1B10, resulting in inhibition in certain types of cancer. According to our previous report, compounds isolated from a medicinal plant, Rhus verniciflua, showed potent inhibitory effects on AKR1B1 (17). R. verniciflua grows mainly in Southeast Asia, and the plant has been reported to have biological activities, such as anti-inflammation (18), anti-cancer (19), and anti-rheumatoid arthritis. Thus, we hypothesized that the ARIs from R. verniciflua could exert similar inhibitory effects on AKR1B10. In the present study, we attempted to isolate these compounds from Rhus verniciflua and evaluated their therapeutic potential as novel inhibitors of AKR1B10 using a recombinant human AKR1B10 (rhAKR1B10). We observed different degrees of AKR1B10 inhibition by the com-http://bmbreports.org BMB reports 
RESULTS AND DISCUSSION
The ethyl acetate fraction shows a strong inhibitory effect on AKR1B10
The present study was carried out in search of new potential AKR1B10 inhibitors from R. verniciflua that would be useful for the treatment of cancer. We have previously reported the inhibitory effects of R. verniciflua extract on AKR1B10 (20). In this study, we further isolated active compounds after bioactivity-guided fractionation to identify those responsible for AKR1B10 inhibitory activity in the extract. We found that, of 5 different fractions isolated, the ethyl acetate fraction showed the most potent inhibitory activity for AKR1B10, with an IC50 value of 1.23 μg/ml (Table 1) . This result prompted us to further isolate active components from the ethyl acetate fraction and to analyze their inhibitory effects.
Butein is a potent inhibitor of AKR1B10
We isolated 9 phenolic compounds from the ethyl acetate fraction and performed spectral analysis for structural elucidation as described in our previous report (17) . All 9 compounds were tested for inhibitory effects on rhAKR1B10 and their results are shown in Table 2 . Among the 9 compounds, the polyphenol butein (Fig. 1A) showed the most potent inhibition against rhAKR1B10, with an IC50 value of 1.47 μM. At equal concentrations of 1 μM, sulfuretin (Fig. 1B) showed about half the potency of butein, and its IC50 value was 3.80 μM. These inhibition patterns are similar to those observed against AKR1B1 in our previous report (17) although the potency of AKR1B1 inhibition was slightly higher. These results support our hypothesis that ARIs can also inhibit AKR1B10 due to their structural similarity. In other words, compounds such as butein may be usable as both anti-diabetic and cancer therapeutic agents, although conventional in vivo and clinical studies should be done before developing them as drugs. Interestingly, AKR1B10 inhibition by other plant polyphenols such as magnolol, honokiol, resveratrol, and dicaffeoyl quinic acid has also been reported recently (21, 22) . To date, another ARI, tolrestat, is known to be the most potent inhibitor for AKR1B10, with an IC50 value in the low nM range (2, 15). Recently, numerous studies have reported that butein exerted anti-cancer effects in human bladder cancer cells and hepatoma cells by inhibition of cellular invasion and by induction of G2-M arrest and apoptosis, respectively (23, 24) . Therefore, butein may exert its anti-cancer effects synergistically through the inhibition of AKR1B10 and the induction of several anti-carcinogenic cellular pathways. Another appli-
